New hope for GIST patients: could velzatinib outperform standard care?
NCT ID NCT07585266
First seen May 13, 2026 · Last updated May 13, 2026
Summary
This study compares a new drug, velzatinib, to the current standard treatment imatinib in people with advanced GIST that has spread or cannot be removed by surgery. About 800 adults who have not had prior treatment for advanced GIST will be randomly assigned to receive either velzatinib or imatinib. The main goal is to see if velzatinib can delay tumor growth or death better than imatinib, while also checking safety and side effects.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for GASTROINTESTINAL STROMAL NEOPLASMS are added.
By submitting, you agree to our Terms of use
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Study contacts
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••
Conditions
Explore the condition pages connected to this study.